India Biosimilar Market Overview
Base Year: 2024
Historical Years: 2019-2024
Forecast Years: 2025-2033
Market Growth Rate: 18.10% (2025-2033)
The India biosimilar market is growing rapidly, driven by rising healthcare demand, regulatory support, affordability, and increasing biologic drug adoption. According to the latest report by IMARC Group, the market is projected to grow at a CAGR of 18.10% from 2025 to 2033.
India Biosimilar Market Trends and Drivers:
The India biosimilar market is experiencing significant growth, driven by the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which require long-term biologic treatments. As original biologics remain costly, biosimilars provide a more affordable alternative, making advanced therapies accessible to a larger population.
Government initiatives aimed at enhancing healthcare accessibility and the rising adoption of biosimilars in public healthcare programs are further propelling market expansion. Additionally, the expiration of patents for several blockbuster biologic drugs has created opportunities for Indian pharmaceutical companies to develop and commercialize biosimilars both domestically and internationally.
Key market trends include advancements in biotechnological research, fostering the development of high-quality, cost-effective biosimilars. Indian pharmaceutical firms are heavily investing in R&D and forming strategic partnerships with global players to strengthen their biosimilar portfolios and expand their reach. Moreover, growing acceptance among healthcare professionals and patients, driven by increasing awareness and confidence in biosimilars’ safety and efficacy, is further supporting market adoption.
Regulatory authorities in India are streamlining approval processes to facilitate biosimilar development and commercialization, contributing to market growth. With the rising demand for affordable biologic therapies, the India biosimilar market is poised for rapid expansion, positioning the country as a key player in the global biosimilar industry.
Request for a sample copy of this report: https://www.imarcgroup.com/india-biosimilar-market/requestsample
India Biosimilar Market Industry Segmentation:
The report has segmented the market into the following categories:
Breakup by Molecule:
- Infliximab
- Insulin Glargine
- Epoetin Alfa
- Etanercept
- Filgrastim
- Somatropin
- Rituximab
- Follitropin Alfa
- Adalimumab
- Pegfilgrastim
- Trastuzumab
- Bevacizumab
- Others
Breakup by Indication Insights:
- Auto-Immune Diseases
- Blood Disorder
- Diabetes
- Oncology
- Growth Deficiency
- Female Infertility
- Others
Breakup by Manufacturing Type:
- In-house Manufacturing
- Contract Manufacturing
Breakup by Region:
- North India
- West and Central India
- South India
- East and Northeast India
Competitive Landscape:
The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.
Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=21512&flag=C
Key highlights of the Report:
- Market Performance (2019-2024)
- Market Outlook (2025-2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: [email protected]
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145